Person:
MİRİOĞLU, ŞAFAK

Loading...
Profile Picture
Status
Kurumdan Ayrılmıştır
Organizational Units
Organizational Unit
Job Title
First Name
ŞAFAK
Last Name
MİRİOĞLU
Name
Email Address
Birth Date

Search Results

Now showing 1 - 7 of 7
  • PublicationMetadata only
    Oxidative stress and macrophage infiltration in IgA nephropathy.
    (2021-11-16T00:00:00Z) Çalışkan, Yaşar; Demir, Erol; Karatay, Ecem; Özlük, Mesude Yasemin; Mirioğlu, Şafak; Dirim, Ahmet Burak; Artan, Ayşe Serra; Usta Akgül, Sebahat; Oto, Özgür Akın; Savran Oğuz, Fatma; Türkmen, Aydın; Lentıne, Krista L.; Yazıcı, Halil; MİRİOĞLU, ŞAFAK
  • PublicationMetadata only
    Lower baseline eGFR levels and IgA nephropathy prediction tool.
    (2021-08-01T00:00:00Z) Artan, Ayşe Serra; Mirioğlu, Şafak; Demir, Erol; Dirim, Ahmet Burak; Şafak, Seda; Garayeva, Nurana; Özlük, Mesude Yasemin; Oto, Özgür Akın; Yazıcı, Halil; Çalışkan, Yaşar; MİRİOĞLU, ŞAFAK
  • PublicationMetadata only
    The importance of glomerular C3 accumulation in elderly patients with primary membranous nephropathy
    (2022-05-01T00:00:00Z) Oto, Özgür Akın; Mirioğlu, Şafak; Dirim, Ahmet Burak; Şafak, Seda; Güller, Nurana; Demir, Erol; Artan, Ayşe Serra; Özlük, Mesude Yasemin; Uçar, Ali Rıza; Soltanova, Lala; Nuriyev, Kanan; Yazıcı, Halil; Çalışkan, Yaşar Kerem; MİRİOĞLU, ŞAFAK
  • PublicationOpen Access
    Middle-term outcomes in renal transplant recipients with COVID-19: a national, multicenter, controlled study
    (2022-02-01T00:00:00Z) Oto, Özgür Akın; Öztürk, Savaş; Arıcı, Mustafa; Velioğlu, Arzu; Dursun, Belda; Guller, Nurana; Şahin, İdris; Eser, Zeynep Ebru; Paydaş, Saime; Trabulus, Sinan; Koyuncu, Sumeyra; Uyar, Murathan; Ural, Zeynep; Sadioglu, Rezzan Eren; Dheir, Hamad; Koc, Neriman Sila; Ozer, Hakan; Durak, Beyza Algul; Gul, Cuma Bulent; Kasapoglu, Umut; Oguz, Ebru Gok; Tanrisev, Mehmet; Kuzgun, Gulsah Sasak; Mirioğlu, Şafak; Dervisoglu, Erkan; Erken, Ertugrul; Gorgulu, Numan; Ozkurt, Sultan; Aydin, Zeki; Kurultak, Ilhan; Ogutmen, Melike Betul; Bakirdogen, Serkan; Kaya, Burcu; Karadag, Serhat; Ulu, Memnune Sena; Gungor, Ozkan; Bakir, Elif Ari; Odabas, Ali Riza; Seyahi, Nurhan; Yildiz, Alaattin; Ates, Kenan; MİRİOĞLU, ŞAFAK
    Background In this study, we evaluated 3-month clinical outcomes of kidney transplant recipients (KTR) recovering from COVID-19 and compared them with a control group. Method The primary endpoint was death in the third month. Secondary endpoints were ongoing respiratory symptoms, need for home oxygen therapy, rehospitalization for any reason, lower respiratory tract infection, urinary tract infection, biopsy-proven acute rejection, venous/arterial thromboembolic event, cytomegalovirus (CMV) infection/disease and BK viruria/viremia at 3 months. Results A total of 944 KTR from 29 different centers were included in this study (523 patients in the COVID-19 group; 421 patients in the control group). The mean age was 46 +/- 12 years (interquartile range 37-55) and 532 (56.4%) of them were male. Total number of deaths was 8 [7 (1.3%) in COVID-19 group, 1 (0.2%) in control group; P = 0.082]. The proportion of patients with ongoing respiratory symptoms [43 (8.2%) versus 4 (1.0%); P Conclusion The prevalence of ongoing respiratory symptoms increased in the first 3 months post-COVID in KTRs who have recovered from COVID-19, but mortality was not significantly different.
  • PublicationMetadata only
    LIMS1 Risk Genotype and T-Cell Mediated Rejection in Kidney Transplant Recipients.
    (2021-04-28T00:00:00Z) Çalışkan, Yaşar; Karahan, Gonca; Usta Akgül, Sebahat; Mirioğlu, Şafak; Özlük, Mesude Yasemin; Yazıcı, Halil; Demir, Erol; Dirim, Ahmet Burak; Türkmen, Aydın; Edwards, John; Oğuz Savran, Fatma; Sever, Mehmet Şükrü; Kiryluk, Krzysztof; Gharavi, Ali; Lentine, Krista L; MİRİOĞLU, ŞAFAK
    Background:This study aims to examine the association of LIM Zinc Finger Domain Containing 1 (LIMS1) genotype with allograft rejection in an independent kidney transplant cohort.Methods:We genotyped 841 kidney transplant recipients for LIMS1 rs893403 variant by Sanger sequencing followed by PCR confirmation of the deletion. Recipients who were homozygous for LIMS1 rs893403 genotype GG were compared to AA/AG genotypes. The primary outcome was T-cell mediated (TCMR) or antibody mediated rejection (ABMR) and secondary outcome was allograft loss.Results:After a median follow-up of 11.4 years, the rate of TCMR was higher in recipients with the GG (n = 200) compared to AA/AG (n = 641) genotypes [25 (12.5%) vs 35 (5.5%); p = 0.001] while ABMR did not differ by genotype [18 (9.0%) vs 62 (9.7%)]. Recipients with GG genotype had 2.4-times higher risk of TCMR than those who did not have this genotype (adjusted hazard ratio (aHR), 1.442.434.12, p = 0.001). A total of 189 (22.5%) recipients lost their allografts during follow up. Kaplan-Meier estimates of 5-year (94.3% vs. 94.4%, p = 0.99) and 10-year graft survival rates (86.9% vs. 83.4%, p = 0.31) did not differ significantly in those with GG compared to AA/AG groups.Conclusions:Our study demonstrates that recipient LIMS1 risk genotype is associated with increased risk of TCMR after kidney transplantation, confirming the role of LIMS1 locus in allograft rejection. These findings may have clinical implications for the prediction and clinical management of kidney transplant rejection by pretransplant genetic testing of recipients and donors for LIMS1 risk genotype.
  • PublicationMetadata only
    Clinical significance of glomerular C3 deposition in primary membranous nephropathy
    (2021-01-01T00:00:00Z) Oto, Özgür Akın; Demir, Erol; Mirioğlu, Şafak; Dirim, Ahmet Burak; Özlük, Mesude Yasemin; Cebeci, Egemen; Baştürk, Taner; Uçar, Ali Rıza; Soltanova, Lala; Nuriyev, Kanan; Kılıçaslan, Işın; Yazıcı, Halil; Çalışkan, Yaşar Kerem; MİRİOĞLU, ŞAFAK
    Background We aimed to investigate the effects of glomerular C3 deposition on clinical, histopathological features, and outcomes of patients with primary membranous nephropathy (MN). Methods A total of 261 patients with biopsy-proven primary MN, who were on follow up for at least 6 months, were included in the study. The patients were grouped according to their C3 immunostaining in kidney biopsy samples at the time of diagnosis: Low intensity [LI; (C3 1 +)] and high intensity [HI; (C3 2 + or C3 3 +)]. The primary outcome was the development of kidney failure. Complete (CR) or partial remission (PR) was defined as secondary outcome. Results Sixteen patients reached the primary outcome after a median follow-up of 33.8 months. Patients in the high intensity group (119 cases) had lower eGFR and higher proteinuria at admission and last follow-up compared to patients in the low intensity group (142 cases). Also, more patients in the high intensity group reached the primary outcome compared to patients in the low intensity group: twelve patients (10.1%) in the high intensity group and four patients (2.8%) in the low intensity group reached the primary outcome (p = 0.015). Kaplan-Meier analysis demonstrated that patients in the high intensity group had a higher risk for kidney failure (p = 0.02). In multivariate logistic regression analysis, high intensity C3 deposition and initial estimated glomerular filtration rate (eGFR) indepenently predicted primary outcome. Conclusion Extensive glomerular C3 deposition is a predictor of kidney failure in patients with MN.
  • PublicationMetadata only
    Amyloid A Amyloidosis After Renal Transplantation: An Important Cause of Mortality
    (2020-08-01T00:00:00Z) Sarıhan, Elif İrem; Çalışkan, Yaşar Kerem; Mirioğlu, Şafak; Özlük, Yasemin; Şenateş, Banu; Seyahi, Nurhan; Baştürk, Taner; Yıldız, Abdülmecit; Kılıçaslan, Işın; Sever, Mehmet Şükrü; MİRİOĞLU, ŞAFAK
    Background. There are limited data on the outcome of transplant recipients with familial Mediterranean fever (FMF)-associated AA amyloidosis. The aim of the present study is to evaluate demographic, clinical, laboratory, and prognostic characteristics and outcome measures of these patients. Methods. Eighty-one renal transplant recipients with FMF-associated AA amyloidosis (group 1) and propensity score-matched transplant recipients (group 2, n = 81) with nonamyloidosis etiologies were evaluated in this retrospective, multicenter study. Recurrence of AA amyloidosis was diagnosed in 21 patients (group 1a), and their features were compared with 21 propensity score-matched recipients with FMF amyloidosis with no laboratory signs of recurrence (group 1b). Results. The risk of overall allograft loss was higher in group 1 compared with group 2 (25 [30.9%] versus 12 [14.8%];P= 0.015 [hazard ratio, 2.083; 95% confidence interval, 1.126-3.856]). Patients in group 1 were characterized by an increased risk of mortality compared with group 2 (11 [13.6%] versus 0%;P= 0.001 [hazard ratio, 1.136; 95% confidence interval, 1.058-1.207]). Kaplan-Meier analysis revealed that 5- and 10-year patient survival rates in group 1 (92.5% and 70.4%) were significantly lower than in group 2 (100% and 100%;P= 0.026 andP= 0.023, respectively). Although not reaching significance, overall, 5- and 10-year graft survival rates (57.1%, 94.7%, and 53.8%, respectively) in group 1a were worse than in group 1b (76.2%, 95%, and 77.8%, respectively;P= 0.19,P= 0.95, andP= 0.27, respectively). Conclusions. AA amyloidosis is associated with higher risk of mortality after kidney transplantation. Inflammatory indicators should be monitored closely, and persistent high levels of acute-phase reactants should raise concerns about amyloid recurrence in allograft.